Efficacy and Safety of Sarclav in the Treatment of Acute Otitis Media in Children Singh Abhay Kumar1,*, Singh Harsimrat2, Singh Himani2 1Assistant Professor, Department of ENT, Saraswathi Institute of Medical Sciences, Hapur (U.P) 2Post Graduate, Department of ENT, Saraswathi Institute of Medical Sciences, Hapur (U.P) *Corresponding Author: Dr Abhay Kumar Singh, Assistant Professor, Department of ENT, Saraswathi Institute of Medical Sciences, Hapur (U.P), E-mail: Abhaysingh2786@gmail.com
Online published on 17 July, 2019. Abstract Background Acute otitis media (AOM) is a community-acquired respiratory tract infection in childhood frequently encountered by primary-care physicians and can cause a significant morbidity. Increasing bacterial resistance has led to concern about the current options for empirical antibiotic treatment and has prompted a search for effective treatments. Objectives To evaluate the clinical efficacy and safety of Sarclav (cefpodoxime proxetil) in the treatment of children with acute otitis media. Patients and Method A prospective, multicenter study was conducted on 1380 children aged from 1 to 13 years with AOM who were prescribed a 5–10 day course of Sarclav (cefpodoxime proxetil) (8 mg/kg/day). Patients were followed-up after 7–14 days from baseline visit. Efficacy was assessed by the percentage of patients with clinical cure, improvement or failure at the follow-up visit. Safety was evaluated by recording the occurrence and severity of any adverse events and by the physicians’ and patients’ assessment of overall tolerability. Results Clinically, 82.5% of patients were cured, 16.4% were improved and there was failure of therapy in 1.1% of the patients. The overall combined cure and improvement rate of all related signs and symptoms was 98.9%. Adverse events, diarrhea and skin rash, were reported by only 16 patients (1.2%). The overall tolerability according to the physicians’ and patients’ assessment was excellent in 93.9% and 88.9%, respectively. Compliance was attained in 99.5% of patients. Conclusion Sarclav (cefpodoxime proxetil) is an effective, safe, well-tolerated antimicrobial agent for treatment of acute otitis media in children. It can be considered as an excellent choice for the empirical treatment of bacterial AOM. Top Keywords Acute otitis media, Sarclav (cefpodoxime), Children, Efficacy. Top |